血清KL-6联合肺超声B线无创筛查特发性炎性肌病相关间质性肺病
该单中心观察性研究纳入162例特发性炎性肌病(IIM)患者,以高分辨率CT为参考标准,确定血清KL-6诊断IIM相关间质性肺病(ILD)的最佳切点为553 U/mL,肺超声B线数推荐阈值为25条,两者联合诊断的曲线下面积(AUC)达0.984,并构建了在线预测模型。
要点
- 血清KL-6≥553 U/mL对IIM-ILD具有较高特异性(95.9%),可作为筛查阈值。
- 肺超声B线数≥25条敏感性达98.8%,适合作为临床筛查阈值。
- KL-6与B线联合诊断AUC为0.984,显著提升无创诊断准确性。
核心结论
- KL-6≥553 U/mL与B线≥25条是有效的IIM-ILD筛查阈值,联合使用可显著提高诊断准确性。
研究设计与样本
- 单中心观察性研究纳入2020至2024年诊断的162例IIM患者,全部接受血清KL-6检测,其中120例接受系统性50点肺超声检查,以HRCT为ILD诊断参考标准。
主要发现
- ILD组(n=113)KL-6水平显著高于非ILD组(n=49)。
- KL-6最佳切点553 U/mL的AUC为0.895,敏感性69%,特异性95.9%。
- 肺超声B线数推荐临床阈值25条,敏感性98.8%。
- KL-6与B线联合诊断AUC为0.984。
- 在快速进展型ILD亚组探索性分析中,KL-6与B线的预测价值仅中等(AUC约0.65)。
关键数值与推荐
- 血清KL-6≥553 U/mL为IIM-ILD筛查阈值(AUC=0.895,敏感性69%,特异性95.9%)。
- 肺超声B线数≥25条为临床筛查阈值(敏感性98.8%)。
- 联合诊断模型AUC=0.984,并实现在线预测工具。
临床怎么用
- 对IIM患者可采用血清KL-6(≥553 U/mL)联合肺超声B线(≥25条)进行无创筛查,减少HRCT辐射暴露。
- 联合模型可用于早期识别IIM-ILD,但快速进展型ILD的预测效能有限,需结合临床综合判断。
局限性
- 单中心观察性设计,样本量有限(162例,其中120例接受肺超声)。
- 快速进展型ILD亚组分析为探索性,预测价值仅中等(AUC约0.65)。
- 结论需在多中心队列中进行外部验证以优化和推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease (ILD) is a major pulmonary complication of idiopathic inflammatory myopathy (IIM), where early diagnosis improves outcomes. While high-resolution CT (HRCT) remains the gold standard, its radiation exposure poses concerns. Serum Krebs von den Lungen-6 (KL-6) and lung ultrasound (LUS) B-lines offer non-invasive alternatives, though their optimal diagnostic cut-offs and combined utility for IIM-ILD remain undefined. This study aimed to establish these cut-offs, evaluate diagnostic performance and develop a clinical prediction model. METHODS: In this single-centre observational study, 162 patients diagnosed with IIM between 2020 and 2024 were enrolled. All underwent serum KL-6 testing, and 120 received systematic 50-point LUS examinations. Using HRCT as the reference standard for ILD diagnosis, receiver operating characteristics (ROC) curve analysis was used to determine optimal cut-offs and construct a combined nomogram. RESULTS: KL-6 levels were significantly elevated in the ILD group (n=113) compared with non-ILD (n=49). The optimal KL-6 cut-off was 553 U/mL (area under the curve (AUC)=0.895, sensitivity 69%, specificity 95.9%). For LUS B-lines number, 25 was recommended as the clinical threshold (sensitivity 98.8%). Their combination enhanced diagnostic performance (AUC=0.984). An online prediction model demonstrated strong clinical applicability. In an exploratory analysis of the rapid-progressive ILD subgroups, KL-6 and B-lines showed only modest predictive value (AUC ≈ 0.65). CONCLUSION: KL-6 ≥553 U/mL and B-lines ≥25 are effective screening thresholds, with combined use significantly improving diagnostic accuracy. The prediction model provides a practical tool for early identification in similar clinical settings. To optimise and generalise its use, external validation in multicentre cohorts is warranted.
引用
- Zhang W, Zheng Q, Zheng S, et al. Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy. RMD Open. 2026. PMID: 42167890. doi:10.1136/rmdopen-2026-006708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。